The Hart-Scott-Rodino antitrust waiting period for the proposed business combination between Personalis and Tempus AI expired on October 2, 2026. This regulatory milestone removes a key closing condition, allowing the transaction to proceed pending stockholder approval at an upcoming meeting. The deal values Personalis at approximately $1.3 billion in cash and stock. Personalis develops personalized cancer testing assays for early detection and treatment guidance.
